{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:10Z","timestamp":1761871090146,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.clml.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T03:36:48Z","timestamp":1521430608000},"page":"e197-e200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Colette","family":"Hanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elie","family":"El Rassy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.clml.2018.03.008_bib1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clml.2018.03.008_bib2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.24204","article-title":"Rituximab with high-dose methotrexate in primary central nervous system lymphoma","volume":"90","author":"Kansara","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.03.008_bib3","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/1097-0142(19800401)45:7<1556::AID-CNCR2820450707>3.0.CO;2-B","article-title":"Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate","volume":"45","author":"Ervin","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.03.008_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ana.20495","article-title":"NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report","volume":"57","author":"Herrlinger","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clml.2018.03.008_bib5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.008_bib6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1200\/JCO.1998.16.3.864","article-title":"High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series","volume":"16","author":"Blay","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.008_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/pbc.24741","article-title":"Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma","volume":"61","author":"Scott","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2018.03.008_bib8","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.03.008_bib9","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.008_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.7326\/0003-4819-105-3-471_3","article-title":"Leukocytoclastic vasculitis after high-dose methotrexate","volume":"105","author":"Navarro","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2018.03.008_bib11","first-page":"675","article-title":"Letter: vasculitis as a complication of high-dose methotrexate in the treatment of acute leukemia","volume":"130","author":"Lanzkowsky","year":"1976","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.clml.2018.03.008_bib12","first-page":"81","article-title":"Leukocytoclastic vasculitis induced by low-dose methotrexate: in\u00a0vitro evidence for an immunologic mechanism","volume":"10","author":"Halevy","year":"1998","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clml.2018.03.008_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mpo.1293","article-title":"Methotrexate-induced systemic vasculitis","volume":"38","author":"Yoruk","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.clml.2018.03.008_bib14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2141.1989.tb04330.x","article-title":"Cutaneous vasculitis after intermediate dose of methotrexate (IDMTX)","volume":"72","author":"Fondevila Carlos","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.008_bib15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/all.12161","article-title":"Desensitization in delayed drug hypersensitivity reactions\u2014an EAACI position paper of the Drug Allergy Interest Group","volume":"68","author":"Scherer","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.clml.2018.03.008_bib16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1398-9995.2010.02441.x","article-title":"General considerations on rapid desensitization for drug hypersensitivity\u2014a consensus statement","volume":"65","author":"Cernadas","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.clml.2018.03.008_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaad.2015.07.010","article-title":"Generalized benign cutaneous reaction to cytarabine","volume":"73","author":"Ruben","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2018.03.008_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4065\/73.3.239","article-title":"Cytosine arabinoside-induced vasculitis","volume":"73","author":"Ahmed","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2018.03.008_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1600-0609.1988.tb00876.x","article-title":"Ara-C vasculitis","volume":"41","author":"Hippe","year":"1988","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.03.008_bib20","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.2003.01.135","article-title":"Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002","volume":"21","author":"Ferreri","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.008_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.008_bib22","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.008_bib23","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1158\/1078-0432.CCR-11-0625","article-title":"Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI","volume":"18","author":"Wieduwilt","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:22Z","timestamp":1761870622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018302155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S2152265018302155"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}